Lastly, CD38 is a widespread antigen which is present on the surface of activated B lymphocytes and may thus be used as the antigenic target for cellular therapies (i.e., CAR-T cells) not only in multiple myeloma but also in non-Hodgkin lymphoma. The gene discussed is CD38; the disease is non-Hodgkin lymphoma.